Guest viewing limit reached
  • You have reached the maximum number of guest views allowed
  • Please register below to remove this limitation

Coluracetam is a nootropic for everything

Gutterpump

Gutterpump

Banned
Coluracetam seems to be the nootropic for everything. Information suggests that it may just be the next contender for the best stand-alone compound. Time will tell as user accounts grow, but for the moment it certainly warrants a test run with the view of becoming a product line. Although it is one of the more expensive compounds, the low dosing schedule and protocol make the price within reason.



General Overview

Coluracetam is the all-rounder of nootropics that is used to enhance focus, mood, memory and creativity. It quite simply appears to do it all and is highly regarded to be one of the best of all the available Racetams.

It has reported to have the greatest improvements in:

-productivity and motivation

-stress

-social anxiety

-short and long term memory

-energy levels

-mood

-sensory perception

Any creative nootropic users out there should consider adding Coluracetam to their stack because the visual effects are on par with Noopept that is enhanced color and clarity. It also adds a certain beauty and depth to things, almost nostalgic, especially outside in nature. Some would even consider it to be psychedelic in nature albeit faintly.

It reportedly stacks well with Oxiracetam, Adderall, Aniracetam and Cannabis.



Dosages

Most users consume Coluracetam in doses ranging from 10mg to 30mg per day. Higher dosages may cause the intensity of the experience to be too intense. Results are said to work instantly and obvious effects last 3-4 hours and you don’t have to worry about tolerance as some users have experience same effects despite daily consumption for 10 months. The subtle benefits may last for days depending on the level of acetylcholine in your system.



Side Effects

Drowsiness at higher dosages has been experienced by some users as well as intermittent nausea. Usually, reducing the dose eliminates these side effects. While some of the more popular Racetams have been known to cause brain fog, insomnia, mood swings, Coluracetam at a lower dosage have minor side effects at best.

Coluracetam is a choline uptake enhancer which is essential for the body to manufacture acetylcholine. Increased amount acetylcholine availability is proven to cause anxiety and depression temporarily. To avoid this situation you should definitely reduce the dose and limit use to one or two times a week.
Click to expand...

Pretty interesting new compound
 
Very much indeed! Would like to hear from users of this...
 
Any good sources to buy from? I'll google it but I'd like to know from anyone who has tried it.
 
jswain34 said:
Any good sources to buy from? I'll google it but I'd like to know from anyone who has tried it.
Click to expand...

I googled it.. And the first link is VERY expensive...
 
Ha. I saw powder city there. I also just read over the examine.com article. They dont seem to be as high on it as the info above.

Edit: at least as of now. No human studies. And it says "coluracetam appears to preserve and/or normalize cholinergic dysfunction in the presence of underactive of chemically impaired HACU, but there is no evidence to support an inherent cognitive boosting effect." HACU = high affinity choline uptake.
 
more info:

The pharmacological properties of MKC-231 (2-(2-oxopyrrolidin-1-yl)-N- (2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl) acetoamide, CAS 135463-81-9) in comparison with an acetylcholinesterase (AChE) inhibitor, tacrine (CAS 1684-40-8) were studied. MKC-231(10(-10)-10(-6) moll) significantly increased high affinity choline uptake (HACU) when it was incubated with the hippocampal synaptosomes of ethylcholine mustard aziridinium ion (AF64A) treated rats, but not of normal rats. MKC-231 did not affect the AChE activity, [3H]- quinuclidinyl benzilate binding, and [3H]-pirenzepine binding. Oral administration of MKC-231 (1-10 mg/kg) significantly improved the learning deficits in the Morris' water maze of AF64A-treated rats, but it did not produce any significant side effects, like tremor, salivation or hypothermia, which were observed in rats treated with high doses of tacrine. Tacrine (0.1-3 mg/kg p.o.) failed to ameliorate the learning deficits in AF64A-treated rats. These results suggest that MKC-231 is a novel and quite unique compound, which improves the memory impairment induced by AF64A through the enhancement of HACU without any side effects at the effective doses.
PMID: 8740080 [PubMed - indexed for MEDLINE]
Click to expand...

Invalid Link Removed
 
jswain34 said:
Ha. I saw powder city there. I also just read over the examine.com article. They dont seem to be as high on it as the info above.
Click to expand...

Naah... I wanted to try out noopept heard it was the sh!t
 
and more (BCI-540 aka Coluracetam):

Favorable Profile

BrainCells identified and selected BCI-540 to develop because of its favorable neurogenic profile similar to antidepressants available on the market today. In addition, BCI-540 appears to act as an AMPA potentiator as well as enhance choline uptake, providing a unique profile that may be optimal for the treatment of both depression and anxiety – an area with a strong market need.
Because it benefits from a novel mechanism that does not act on serotonin or norepinephrine receptors, BCI-540 has the potential to treat unresponsive and partially responsive patients with depression, especially in those patients that present with concomitant anxiety. In addition, potential improvements in safety and tolerability may help further differentiate this drug candidate from SSRIs and SNRIs.
Identified in a Different Indication

BrainCells in-licensed BCI-540 from Mitsubishi Pharmaceutical Corporation in August 2006 and is currently developing it for the treatment of patients with Major Depressive Disorder (MDD) and anxiety. Mitsubishi Pharma had previously developed the compound extensively in a different CNS indication, then suspended the program when the drug met safety expectations but did not reach the defined efficacy endpoints. BrainCells has repositioned the drug and has completed an exploratory Phase 2a study in depression with anxiety.
Clinical Results

Results from the Phase 2a trial suggest BCI-540 has the potential to treat a difficult-to-treat population, people with MDD who have failed previous treatments, and have a co-morbid anxiety disorder.
Click to expand...
 
From a press release (linked below):

SAN DIEGO, Calif., June 14, 2010 – BrainCells Inc., a company leading the scientific research
of neurogenesis using its proprietary neural stem cell platform technology to identify novel
compounds for the treatment of central nervous system (CNS) diseases, announced today
findings from an exploratory, dose ranging Phase 2a clinical trial not powered for statistical
significance. The trial evaluated BCI-540 for the treatment of patients with major depressive
disorder (MDD) with anxiety who had previously failed an average of two antidepressants. While
there was no difference between the overall treatment group and placebo on scales for
depression and anxiety, further analysis showed a positive efficacy signal in a subset of patients
with MDD and general anxiety disorder (GAD), which warrants further study.

“Co-morbid depression and anxiety remains a significant unmet need, representing
approximately 40 percent of depressed patients. BCI-540 elicited a stronger response in this
group of patients, providing us direction for additional studies to better understand its
therapeutic potential,” said Allan Young, MB, ChB, Ph.D., FRCPsych, FRCPC, director of the
Institute of Mental Health at the University of British Columbia and lead investigator of the trial. “I
look forward to its next step in development.”

The six-week trial was randomized, double-blind and placebo-controlled to determine whether
80 milligrams of BCI-540 dosed orally once or three times daily (TID) improves symptoms in
patients with MDD and anxiety who had previously failed an average of two antidepressants.
The trial measured change from baseline at week two, four and six for 101 evaluable patients
with a variety of commonly used patient and physician-rated scales including the Hamilton
Rating Scales for Anxiety (HAM-A) and Depression (HAM-D).

At week six, in the overall population there was no benefit of BCI-540 on HAM-A or HAM-D
compared to placebo. However, in patients who were dosed TID, 36% responded compared to
19% in the placebo group. Within this group, depression symptoms of those with co-morbid
GAD improved by 12.2 points on HAM-D compared to 5.5 points in the placebo group
(p<0.008). BCI-540 was well tolerated, with a side effect profile similar to placebo.

“Neurogenesis is an exciting new field that is demonstrating potential in many different CNS
diseases including depression and anxiety,” said Carrolee Barlow, M.D., Ph.D., chief scientific
and medical officer at BrainCells. “BCI-540 began to separate from placebo by four weeks,
which is in line with our understanding of how neurogenesis progresses in the brain. It is an
important clinical finding that we’ll take forward as we investigate the therapeutic opportunity of
BCI-540 in this difficult-to-treat population.”

BCI-540 is a bifunctional molecule that works to treat mood disorders through two mechanisms
of action, AMPA potentiation and choline uptake enhancement. BrainCells identified through its
platform the compound’s ability to help new neurons differentiate and survive, two important
aspects of the neurogenesis process. Experiments conducted by BrainCells confirmed
appropriate changes in behavioral models for depression, without affecting serotonin levels,
potentially eliminating side effects typically associated with selective serotonin reuptake
inhibitors (SSRIs) like Prozac. Currently, only 30 to 40 percent of people with depression fully
respond to current treatments.
Click to expand...

Invalid Link Removed
 
In for info
 
You must log in or register to reply here.
Back
Top